ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer
October 28, 2020 4:00 pmBy Andrew D. Bowser
However, trials investigating retreatment are underway, so this recommendation may change.
The guidelines, from … Read more
Tag: Niraparib
Halting Cancer by Halting DNA Repair
September 25, 2020 11:00 amBy Liam Drew
PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could expose a weak … Read more
ASCO Releases New Guidelines on PARP Inhibitor Use for Management of Ovarian Cancer
September 1, 2020 2:00 pmBy Hannah Slater
The recommendations were based on a review of 17 clinical trials, FDA approvals, and consensus where evidence was lacking.
The American Society for Clinical Oncology (ASCO) published new guidelines on the use of PARP inhibitors in the … Read more
Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer
June 5, 2020 8:00 amThe combination use of niraparib plus bevacizumab significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer.
The combination use of niraparib (Zejula) plus bevacizumab (Avastin) significantly improved clinical outcomes, compared with niraparib … Read more
FDA Approves Niraparib for Advanced Ovarian Cancer
April 29, 2020 10:00 amBy Hannah Slater
The FDA approved niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.1
Efficacy for … Read more
Frontline Niraparib Plus Bevacizumab for Advanced Ovarian Cancer Yields Promising Activity
April 13, 2020 12:00 pmBy Gina Columbus
Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II … Read more
More Evidence Supporting the Clinical Benefit of Niraparib Maintenance Therapy After Chemo in Advanced Ovarian Cancer
March 31, 2020 12:00 pmBy Susan Moench, PhD, PA-C
Preliminary assessments of secondary study endpoints of a phase 3 clinical trial evaluating maintenance therapy with niraparib, an inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP), compared with placebo in patients with newly diagnosed advanced ovarian … Read more
New Research Shows Which Ovarian Cancer Patients Won’t Benefit From Immune-PARP Combo
March 19, 2020 10:10 amBOSTON – In patients with advanced ovarian cancer, a combination of drugs known as immune checkpoint inhibitors and PARP inhibitors can produce powerful remissions, clinical trials have shown, but up until now investigators haven’t been able to predict which patients … Read more
FDA Approves Zejula for Advanced Ovarian Cancer Subset
October 23, 2019 3:30 pmBy Jessica Skarzynski
The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous … Read more
PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Cancer?
September 29, 2019 6:00 pmBy Ed Susman
PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines.
Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy, then were treated with niraparib (Zejula), had a significantly reduced risk … Read more
Can Recurrent Ovarian Cancer Patients Avoid Chemotherapy?
September 20, 2019 8:00 pmBy Dave Levitan
The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more
Chemo-Free Combo Boosts PFS in Recurrent Ovarian Cancer
June 4, 2019 6:00 pmBy Ian Ingram
Benefit seen across all subgroups for patients with platinum-sensitive disease.
Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more
Niraparib Offers New Option in Heavily Pretreated Ovarian Cancer
April 17, 2019 7:00 pmBy Dave Levitan
Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.
“Although most … Read more
Individualized Dosing Regimen Reduces Side Effects in Ovarian Cancer Maintenance Therapy
March 18, 2019 7:00 pmBy Kristie L. Kahl
Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose, according to a recent analysis
… Read morePARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Cancer
March 17, 2019 6:00 pmBy Ian Ingram
In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.
Compared with placebo, … Read more
Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer
October 25, 2018 1:11 amReal-world experience of adverse events with the oral PARP inhibitor niraparib in patients with platinum-sensitive recurrent ovarian cancer at a 200 mg daily dose differed from those most commonly seen in the phase 3 clinical trial at … Read more
Quality of Life Maintained With Niraparib for Ovarian Cancer
August 1, 2018 9:19 pmby Madeline Marr
The use of niraparib in women receiving treatment for platinum-sensitive recurrent ovarian cancer did not adversely affect quality of life (QoL), according to a study published in The Lancet Oncology.
An international team of researchers led … Read more
Non-Chemo Combo Active in Ovarian Cancer
June 6, 2018 7:00 pmThe combination of two targeted agents – the PARP inhibitor niraparib (Zejula) plus the checkpoint inhibitor pembrolizumab (Keytruda) — appears to elicit a durable response among women with heavily pretreated, refractory ovarian cancer, researchers reported here.
About 25% of women … Read more
SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer
April 2, 2018 5:19 pmA combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more
Niraparib Maintains Quality of Life
September 13, 2017 8:40 pmAdministering niraparib to patients with recurrent ovarian cancer after a complete response (CR) or partial response (PR) to platinum-based chemotherapy may allow patients to continuously maintain their quality of life (QOL) during treatment, according to a study presented at the … Read more